Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib vs tocilizumab in pediatric systemic juvenile idiopathic arthritis
2022-501599-25-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Mar 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial in systemic juvenile idiopathic arthritis (SJIA) comparing Upadacitinib arm with Tocilizumab (RoActemra) reference arm (2 arms). Primary endpoint: Adapted sJIA ACR 30 response at Week 12. Planned start Mar 2024; status: authorised.
02
Drugs
upadacitinibtocilizumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on 2022-501599-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501599-25-00.